Fox Run Management L.L.C. Has $540,000 Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Fox Run Management L.L.C. cut its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 42.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 8,216 shares of the biotechnology company's stock after selling 6,150 shares during the quarter. Fox Run Management L.L.C.'s holdings in BioMarin Pharmaceutical were worth $540,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. TD Private Client Wealth LLC boosted its position in shares of BioMarin Pharmaceutical by 57.4% in the 3rd quarter. TD Private Client Wealth LLC now owns 510 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 186 shares during the last quarter. SBI Securities Co. Ltd. bought a new stake in BioMarin Pharmaceutical in the fourth quarter valued at about $36,000. True Wealth Design LLC lifted its stake in BioMarin Pharmaceutical by 13,400.0% in the third quarter. True Wealth Design LLC now owns 810 shares of the biotechnology company's stock valued at $57,000 after buying an additional 804 shares during the period. Smartleaf Asset Management LLC boosted its holdings in BioMarin Pharmaceutical by 111.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 885 shares of the biotechnology company's stock worth $58,000 after buying an additional 466 shares during the last quarter. Finally, UMB Bank n.a. grew its position in shares of BioMarin Pharmaceutical by 260.1% during the 4th quarter. UMB Bank n.a. now owns 1,019 shares of the biotechnology company's stock worth $67,000 after buying an additional 736 shares during the period. Institutional investors and hedge funds own 98.71% of the company's stock.

Remove Ads

BioMarin Pharmaceutical Stock Down 1.9 %

NASDAQ:BMRN traded down $1.39 on Friday, hitting $71.44. 1,245,485 shares of the company's stock were exchanged, compared to its average volume of 1,843,958. The company has a market cap of $13.63 billion, a P/E ratio of 32.47, a price-to-earnings-growth ratio of 0.61 and a beta of 0.33. The firm has a 50-day moving average price of $67.46 and a 200-day moving average price of $67.63. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.33 and a quick ratio of 2.62. BioMarin Pharmaceutical Inc. has a 52 week low of $60.63 and a 52 week high of $94.85.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last issued its quarterly earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 EPS for the quarter, beating the consensus estimate of $0.54 by $0.18. The firm had revenue of $747.31 million during the quarter, compared to analysts' expectations of $711.05 million. BioMarin Pharmaceutical had a return on equity of 9.91% and a net margin of 14.96%. As a group, analysts expect that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on BMRN shares. Royal Bank of Canada restated a "sector perform" rating and set a $70.00 price objective on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Piper Sandler upped their price objective on shares of BioMarin Pharmaceutical from $122.00 to $126.00 and gave the company an "overweight" rating in a research report on Thursday, February 20th. StockNews.com upgraded BioMarin Pharmaceutical from a "buy" rating to a "strong-buy" rating in a report on Tuesday, March 18th. Bank of America boosted their target price on BioMarin Pharmaceutical from $99.00 to $103.00 and gave the company a "buy" rating in a research note on Thursday, February 20th. Finally, Scotiabank raised their price target on BioMarin Pharmaceutical from $78.00 to $80.00 and gave the stock a "sector perform" rating in a research report on Thursday, February 20th. Seven research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $94.00.

Insider Activity

In related news, CAO Erin Burkhart sold 1,344 shares of the firm's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $68.38, for a total value of $91,902.72. Following the completion of the sale, the chief accounting officer now directly owns 13,105 shares in the company, valued at approximately $896,119.90. This trade represents a 9.30 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 1.85% of the stock is currently owned by insiders.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.